Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Cardinal Health, Inc.'s acquisition of three nuclear pharmacies from Biotech was anticompetitive and reduced competition for low-energy radiopharmaceuticals in Las Vegas, Nevada; Albuquerque, New Mexico; and El Paso, Texas. Settlement of the FTC's charges requires Cardinal to reconstitute and sell nuclear pharmacies in the three cities.
The Commission vote approving the final order, and letter to a member of the public who commented on it, was 4-0. The order can be found on the FTC's website and as a link to this press release. Public comments can be found here on the FTC's website. (FTC File No. 091-0136; the staff contact is Leonard Gordon, Director, FTC Northeast Region, 212-607-2801; see press release dated July 21, 2011.)
The Federal Trade Commission works to promote competition, and to protect and educate consumers. The FTC will never demand money, make threats, tell you to transfer money, or promise you a prize. You can learn more about how competition benefits consumers, file an antitrust complaint, or comment on a proposed merger. For the latest news and resources, follow the FTC on social media, subscribe to press releases, and read our blog.
Contact Information
202-326-2180